SPRY
ARS Pharmaceuticals, Inc
4.30$
+0.1%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +0.0% | -75.0% | +42.8% | -12.1% | -30.0% | -59.3% | -796.3% | – | -50.0% | -100.0% | – | – | – | +313.6% | +4,086.7% | -90.8% | +97.1% | +106.8% | -13.6% | -19.2% | +48.4% | – | |
| – | +1.5% | +0.5% | +15.4% | +1,108.3% | +0.0% | -8.8% | -23.6% | +38.6% | -19.8% | -12.8% | -6.3% | +81.5% | +11.7% | -58.4% | +13.4% | +53.8% | +31.8% | -98.4% | +3,375.0% | +4.0% | +23.2% | +64.3% | -60.9% | +96.3% | +104.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +4,127.5% | -95.3% | +173.3% | +126.5% | +2.4% | -34.1% | +26.9% | – | |
| – | -31.9% | +16.7% | +73.4% | -35.0% | +0.0% | -8.8% | -23.6% | +38.6% | -19.8% | -10.5% | +21.0% | +39.1% | +11.5% | -58.9% | +13.4% | +53.8% | +31.8% | -35.9% | -31.6% | -2.5% | +36.7% | -31.8% | +25.2% | +25.9% | +8.3% | – | |
| – | – | – | – | – | +0.0% | +9.7% | +76.2% | +29.9% | +5.1% | +19.0% | +266.8% | +13.5% | +9.2% | +12.6% | -54.4% | +16.7% | +12.4% | +115.6% | +87.7% | +13.6% | +32.1% | +37.6% | -19.8% | +20.4% | +7.4% | – | |
| – | -25.9% | +25.2% | +108.5% | -92.6% | +0.0% | +9.7% | +76.2% | +29.9% | +5.1% | +23.1% | +292.9% | +3.3% | +9.2% | +11.7% | -54.4% | +16.7% | +12.4% | +165.0% | +49.7% | +15.8% | +41.9% | +32.8% | -14.4% | +15.4% | +7.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -178.8% | – | – | – | – | – | – | |
| – | -5.1% | -89.2% | – | – | – | – | – | – | +144.4% | +191.3% | -79.7% | +1,621.1% | – | – | – | – | – | – | – | – | – | – | – | -6.1% | +1.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -167.6% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | -344.4% | – | – | -1,636.9% | – | – | – | -100.8% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -168.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -167.0% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.